Candriam S.C.A. Akero Therapeutics, Inc. Transaction History

Candriam S.C.A.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$17.76 - $31.18 $994,560 - $1.75 Million	56,000 Added 30.43%	240,000 $6.06 Million
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $955,920 - $4.23 Million	84,000 Added 84.0%	184,000 $4.3 Million
Q3 2023 Nov 13, 2023	SELL	$41.19 - $52.25 $617,850 - $783,750	-15,000 Reduced 13.04%	100,000 $5.06 Million
Q2 2023 Aug 08, 2023	BUY	$36.89 - $56.88 $368,900 - $568,800	10,000 Added 9.52%	115,000 $5.37 Million
Q1 2023 May 12, 2023	SELL	$37.27 - $50.24 $3.91 Million - $5.28 Million	-105,000 Reduced 50.0%	105,000 $4.02 Million
Q4 2022 Feb 13, 2023	BUY	$33.44 - $54.8 $7.02 Million - $11.5 Million	210,000 New	210,000 $11.5 Million
Q1 2022 May 13, 2022	SELL	$12.97 - $22.26 $1.15 Million - $1.98 Million	-88,876 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$19.87 - $26.24 $750,907 - $991,635	-37,791 Reduced 29.83%	88,876 $1.88 Million
Q2 2021 Jul 20, 2021	BUY	$24.81 - $32.35 $750,973 - $979,202	30,269 Added 31.4%	126,667 $3.14 Million
Q4 2020 Jan 22, 2021	SELL	$25.12 - $29.89 $77,922 - $92,718	-3,102 Reduced 3.12%	96,398 $2.49 Million
Q3 2020 Oct 19, 2020	SELL	$30.79 - $39.92 $1.8 Million - $2.34 Million	-58,500 Reduced 37.03%	99,500 $3.06 Million
Q2 2020 Jul 23, 2020	BUY	$19.25 - $26.76 $2.66 Million - $3.69 Million	138,000 Added 690.0%	158,000 $3.94 Million
Q2 2019 Aug 01, 2019	BUY	$18.08 - $19.83 $361,599 - $396,599	20,000 New	20,000 $381,000

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.36B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.